Stockreport

Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for YUSIMRY®, a Biosimilar of Humira® [Yahoo! Finance]

Coherus BioSciences, Inc.  (CHRS) 
Last coherus biosciences, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.coherus.com
PDF YUSIMRY ® is currently approved by the U.S. FDA for nine indications and is available at a lower cost compared to Humira ® ; Meitheal expects additional indications, in [Read more]